T1	Participants 114 146	subjects with metabolic syndrome
T2	Participants 320 358	subjects with metabolic syndrome (MS).
T3	Participants 359 388	Participants with MS (n = 54)
T4	Participants 870 939	Forty-two subjects completed the study (placebo, n = 19; WGP, n = 23)
T5	Participants 1410 1426	subjects with MS
